Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Dec 26;12(12):1511-1528.
doi: 10.4252/wjsc.v12.i12.1511.

Prospects for the therapeutic development of umbilical cord blood-derived mesenchymal stem cells

Soyoun Um  1 , Jueun Ha  2 , Soo Jin Choi  3 , Wonil Oh  3 , Hye Jin Jin  4
Affiliations
Review

Prospects for the therapeutic development of umbilical cord blood-derived mesenchymal stem cells

Soyoun Um et al. World J Stem Cells. .

Abstract

Umbilical cord blood (UCB) is a primitive and abundant source of mesenchymal stem cells (MSCs). UCB-derived MSCs have a broad and efficient therapeutic capacity to treat various diseases and disorders. Despite the high latent self-renewal and differentiation capacity of these cells, the safety, efficacy, and yield of MSCs expanded for ex vivo clinical applications remains a concern. However, immunomodulatory effects have emerged in various disease models, exhibiting specific mechanisms of action, such as cell migration and homing, angiogenesis, anti-apoptosis, proliferation, anti-cancer, anti-fibrosis, anti-inflammation and tissue regeneration. Herein, we review the current literature pertaining to the UCB-derived MSC application as potential treatment strategies, and discuss the concerns regarding the safety and mass production issues in future applications.

Keywords: Immunomodulation; Mesenchymal stem cell; Regenerative medicine; Stem cell therapy; Therapeutic cell manufacturing processing; Umbilical cord blood.

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest statement: The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Mechanisms of action mediated by umbilical cord blood-derived mesenchymal stem cells. SDF: Stromal cell-derived factor; VCAM: Vascular cell adhesion molecule; MMP: Matrix metalloproteinase; HGF: Hepatocyte growth factor; PDGF: Platelet-derived growth factor; MCP: Monocyte chemoattractant protein; FGF: Fibroblast growth factor; PTX: Pentraxin-related protein; TGF: Transforming growth factor; TRAIL: Tumor necrosis factor-related apoptosis-inducing ligand; GDF: Growth/differentiation factor; ICAM: Intercellular adhesion molecule; BDNF: Brain-derived neurotrophic factor; VEGF: Vascular endothelial growth factor; FGF: Fibroblast growth factor; UCB: Umbilical cord blood; MSC: Mesenchymal stem cell.
Figure 2
Figure 2
Workflow for therapeutic cell manufacturing processing.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Friedenstein AJ. Precursor cells of mechanocytes. Int Rev Cytol. 1976;47:327–359. - PubMed
    1. Perdikogianni C, Dimitriou H, Stiakaki E, Martimianaki G, Kalmanti M. Could cord blood be a source of mesenchymal stromal cells for clinical use? Cytotherapy. 2008;10:452–459. - PubMed
    1. Baer PC, Koch B, Hickmann E, Schubert R, Cinatl J Jr, Hauser IA, Geiger H. Isolation, Characterization, Differentiation and Immunomodulatory Capacity of Mesenchymal Stromal/Stem Cells from Human Perirenal Adipose Tissue. Cells. 2019;8:1346. - PMC - PubMed
    1. Jiang Y, Jahagirdar BN, Reinhardt RL, Schwartz RE, Keene CD, Ortiz-Gonzalez XR, Reyes M, Lenvik T, Lund T, Blackstad M, Du J, Aldrich S, Lisberg A, Low WC, Largaespada DA, Verfaillie CM. Pluripotency of mesenchymal stem cells derived from adult marrow. Nature. 2002;418:41–49. - PubMed
    1. Gluckman E, Broxmeyer HA, Auerbach AD, Friedman HS, Douglas GW, Devergie A, Esperou H, Thierry D, Socie G, Lehn P. Hematopoietic reconstitution in a patient with Fanconi's anemia by means of umbilical-cord blood from an HLA-identical sibling. N Engl J Med. 1989;321:1174–1178. - PubMed